Verastem (VSTM) said Monday that the US Food and Drug Administration accepted for review the new drug application for avutometinib in combination with defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer that received at least one systemic treatment and have KRAS mutation.
The FDA granted priority review to the new drug application and has set an action date of June 30, according to the company.
There are currently no approved treatments for low-grade serous ovarian cancer, Verastem added.
The new drug application is based on results from the Phase 2 Ramp 201 study that showed avutometinib plus defactinib had a substantial overall response rate.
Shares of the company were up 22% in recent after-hours activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.